ClinicalTrials.gg
RecruitingNCT07531511SPIRITUpdated Jul 31, 2026

SLC6A1-NDD Prospective Longitudinal Natural History Study

An observational study in SLC6A1 Neurodevelopmental Disorder (NDD) and Developmental and Epileptic Encephalopathies (DEE), sponsored by UCB Biopharma SRL. Recruiting at 3 sites in 3 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies in Neurodevelopmental Disorders with a site in United States — 37 open to participants now, 53 under way, 9 of them phase 3. Neurodevelopmental Disorders · United States.

Planned enrollment
28th of 40
60 · median 158
Started
2026
with 10 others
Observational
40 of 100
19 open now
Primary completion
2029-05
later than 42 of 52 live
Registered
95th of 100
by date

Among the 100 studies in Neurodevelopmental Disorders with a site in United States, this one is the 28th largest by planned enrollment of the 40 observational ones that give a count, is one of 11 that started in 2026, is one of 40 observational ones, reaches primary completion later than 42 of the 52 other live ones, and was the 95th registered.

Neurodevelopmental Disorders

355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.

Browse Neurodevelopmental Disorders studies →

Open to participants now

37 of the 100 studies in Neurodevelopmental Disorders with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Neurodevelopmental Disorders with a site in United States, or all of them as a file.
02

Study summary

The overall objective of this prospective longitudinal natural history study is to collect clinical data to characterize and evaluate the natural course of SLC6A1-NDD and assess the feasibility of certain assessments for the purpose of conducting future clinical studies in patients with this disease.

Read the detailed description

GTEP01 is a noninterventional, multicenter, multinational, prospective longitudinal natural history study that will be conducted in different countries/languages to prepare for future international clinical studies.

The aim of this study is to characterize the natural course of SLC6A1-NDD through collecting clinical data longitudinally.

Approximately 60 patients with SLC6A1-NDD are planned to be enrolled within 2 age groups, a minimum of approximately 20 patients in each of the 2 age groups. The study consists of Enrollment and Baseline visits followed by 5 study visits over a 2-year Observational Period.

03

Conditions studied

  • SLC6A1 Neurodevelopmental Disorder (NDD)
  • Developmental and Epileptic Encephalopathies (DEE)

Keywords

  • SLC6A1- NDD
  • Natural history study
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population comprises pediatric patients with a diagnosis of SLC6A1-NDD.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a diagnosis of SLC6A1-NDD characterized by epilepsy, global developmental delay, autism spectrum disorder, or intellectual disability, with a documented history of an SLC6A1 mutation, defined as pathogenic or likely pathogenic by the Investigator.
  • Patients should not be older than 17 years at time of assent/consent.
  • Patients under the age of 18 years with legal guardians providing . Assent will be obtained from any patients judged to have sufficient capacity to provide assent at the discretion of the Investigator.
  • Patient and patient's caregiver are willing and able to comply with study requirements (including diary completion and visit schedule).

Exclusion criteria

Exclusion Criteria:

  • Patients and their caregivers are unable to complete follow-up visits.
  • Patients with a history of an alternate diagnosis for disease, including a genetic cause, which is known to contribute to epilepsy or NDD.
  • Patient is currently receiving an product(s) other than 4-phenylbutyrate or has received an investigational product within 30 days or within \<5 times the half-life of the investigational product, whichever is longer, prior to the Enrollment Visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Age group 1 (< 6 years)

    This age group consists of patients which are \< 6 years at the time of study enrollment.

  • Age group 2 (6 to 17 years)

    This age group consists of patients which are between 6 and 17 years at the time of study enrollment.

06

What researchers measure

Primary outcomes

  1. Seizure frequency by type (countable seizures per 28 days) by visit as compared to Baseline

    Time frame: 2 years

  2. Seizure free days per 28 days by visit as compared to Baseline

    Time frame: 2 years

Secondary outcomes

  1. Number and proportion of tests completed by visit

    Number and proportion of scheduled assessments completed by participants at each study visit for domains relevant to the natural history of SLC6A1 NDD, including epileptic seizures, neurodevelopment, behavioral, communication, sleep, and overall symptom severity.

    Time frame: 2 years

  2. Patient retention (dropout by visit and reason for dropout)

    Time frame: 2 years

  3. EEG over time: Number/proportion of tests completed by study patients by visit

    Time frame: 2 years

07

Study locations

3 of 3 sites recruiting
  • Gtep01 50614
    New York, New York 10021, United States
    Recruiting
  • Gtep01 40131
    Strasbourg, France
    Recruiting
  • Gtep01 40870
    Madrid, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Not yet confirmed

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2029, 34 months after the start.

Of 70 observational studies under Neurodevelopmental Disorders, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 140. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 15, 2026
StartActual
Jul 21, 2026
Primary completionEst.
May 25, 2029
CompletionEst.
May 25, 2029
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07531511
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Jul 21, 2026
Primary completion
May 25, 2029 (estimated)
Completion
May 25, 2029 (estimated)
Last update
Jul 31, 2026

Study contacts

UCB Cares
Contact
ucbcares@ucb.com
+18445992273
UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion